Tainan City, Taiwan, July 17, 2018 — Handa Pharmaceuticals, Inc. (Taiwan Exchange: 6620) (“Handa”), summons an investor meeting to present the following information to institutional investors.
“Handa is pleased to announce the rollout of its unique and creative ONCORE® drug delivery technology platform” applicable to the development of 505 (b)(2) new drugs, said Bill Liu, Ph.D., Handa’s Chairman and CEO. “Utilizing its ONCORE™ technology platform, Handa will be able to decrease, minimize or even overcome certain limitations of existing oncology medicines, making them safer and easier to take for the cancer patients who rely on them in order to lift patients life quality.
Given the fact the competitions of the generic drugs are so fierce, Handa since the beginning of 2017has actively transferred and upgraded its operations by focusing on the development of 505 (b)(2) new drug, protectable by patents. In the year of 2018, Handa expects to inject US$6,000,000 into the R & D of 505 (b)(2) new drugs. It is foreseeable for Handa to secure long-term and stable revenues and profits in relevant markets in the very near future.
On November 2016, the first-to-file high barrier generic drug, Quetiapine XR Tablet, co-developed by Handa group and its cooperative partner, Par Pharmaceuticals, Inc., was launched in the US market, which brought about a numerous amount of revenues to Handa. In 2017, Handa claimed NT$2.81 profit per share. It is one of the top performers on the emerging market.
In the meantime, Handa’s partner, Par Pharmaceuticals, Inc., further secures the final approval from the FDA of the United States on April 2017 for another drug, Dexlansoprazole DR Capsules, using to cure gastro esophageal reflux disease. This is an exploding first-to-file generic drug in the US market. Handa’s strategic partner, Fosun Pharmaceuticals Inc., will be responsible for the product registration with the CFDA and distribution in the Chinese market.
Handa is a specialty pharmaceutical company focusing on the research and development of innovative prescription drug design as well as drug dosage. Handa stands foot on Taiwan to expand its global operations and centralizes its drug dosage R & D. Additionally, Handa goes through its US subsidiary, Handa Pharmaceuticals, LLC. and grand-son subsidiary, Handa Hangzhou Pharmaceuticals Technology Ltd., to penetrate into the top two pharmaceutical markets of the globe, the United States and Mainland China.
Dr. Liu emphasizes in the meeting that “R & D” is the core value of Handa. Handa owns the capability and experience on drug research internationally. Handa is focusing on development of high market value 505 (b)(2) new drug and high barrier niche generic drug. Handa will pursue and achieve the goal of continuous, stable and perseverant operations, by the model of co-developing drugs with big pharm companies or licensing out mechanism to decrease the operational risks and exposures.
Cautionary Statement Regarding Forward-Looking Information
This release contains various forward-looking statements, including, without limitation, those statements with respect to markets, revenues and operations. All such forward-looking statements are only management’s estimates at the present time. No assurances can be made that any of these estimates will materialize. The estimates are based upon current information and certain external factors, some of which are beyond the control of the Company. The estimates are subject to various assumptions. Many of these assumptions may not be correct and are subject to risks such as unforeseen market changes and supply chain disruptions.
Investor Relations Contact:
Stephen Chen
CFO
Handa Pharmaceuticals, Inc.
3F, No 74, Zhouzi St., Neihu Dist., Taipei City 11493, Taiwan (R.O.C.)
TEL：+886-2-8751-8717 ext 32
E-MAIL：stephensy@handapharma.com.tw